EORTC 22996-24002/TROG 01.01 - EPO Head & Neck

By w.paterson
14 August, 2021
0 Comments

A Phase III Double-Blind, Randomized, Placebo-Controlled Study of Erythropoietin When Used as an Adjuvant to Radiation Therapy in Patients With Head & Neck Squamous Cell Carcinoma

Primary Sponsor

EORTC

Collaborating Groups

TROG Cancer Research

15 July, 2025

New paper outlines protocol for important TROG 20.01 CHEST-RT lung cancer trial

TRIAL UPDATE: 15 July 2025 The TROG 20.01 CHEST-RT

8 July, 2025

Recruitment Milestone Achieved for TROG 19.06 DECREASE Trial

TRIAL UPDATE: 8 July 2025 The TROG 19.06 DECREASE

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A Phase III Double-Blind, Randomized, Placebo-Controlled Study of Erythropoietin When Used as an Adjuvant to Radiation Therapy in Patients With Head & Neck Squamous Cell Carcinoma

EORTC/TROG 01.03 – Glioblastoma/Temozolomide – 26981/22981

TROG 99.06 – Bladder (Phase II)

Related Post

New paper outlines protocol for important TROG 20.01 CHEST-RT lung cancer trial

Recruitment Milestone Achieved for TROG 19.06 DECREASE Trial

EORTC 22996-24002/TROG 01.01 – EPO Head & Neck

A Phase III Double-Blind, Randomized, Placebo-Controlled Study of Erythropoietin When Used as an Adjuvant to Radiation Therapy in Patients With Head & Neck Squamous Cell Carcinoma

EORTC/TROG 01.03 – Glioblastoma/Temozolomide – 26981/22981

TROG 99.06 – Bladder (Phase II)

Related Post

New paper outlines protocol for important TROG 20.01 CHEST-RT lung cancer trial

Recruitment Milestone Achieved for TROG 19.06 DECREASE Trial